Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

This study is ongoing, but not recruiting participants.
Rutgers Cancer Institute of New Jersey
Columbia University
Winship Cancer Institute of Emory University
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center Identifier:
First received: February 23, 2006
Last updated: September 11, 2014
Last verified: September 2014